The COMP360 Phase 3 pivotal program in treatment-resistant depression is designed to generate the evidence required for regulatory approval and to ensure commercial success through integration into healthcare systems. The company is on track to start the Phase 3 program this year and is making steady progress toward establishing the full global footprint for this program, which includes actively initiating new sites and training therapists.